H.R. 1672 · 119th Congress

Maintaining Investments in New Innovation Act

Introduced on Feb 27, 2025 by Donald G. Davis (D-NC-1). 51 cosponsors, 44 of them from another party. Latest action (Feb 27, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Stage
Introduced
Introduced
Feb 27, 2025
Cosponsors
51
44 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

Subjects

  • Genetics
  • Medicare
  • Prescription drugs

Summary

By the Congressional Research Service (Introduced in House, Feb 27, 2025). Public domain.

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Donald G. DavisD-NC-1Sponsor

Democrats · 7

Republicans · 44

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Feb 27, 2025Introduced in House
  2. Feb 27, 2025Introduced in House
  3. Feb 27, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Feb 27, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. ALNYLAM PHARMACEUTICALS, INC.29 reports
    $880K reported (all issues)
  2. NOVARTIS CORPORATION23 reports
    $13.1M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  3. IONIS PHARMACEUTICALS, INC.11 reports
    $760K reported (all issues)
  4. HealthCare Institute of New Jersey7 reports
    $333.2K reported (all issues)
  5. AMGEN INC.6 reports
    $18.3M reported (all issues)Federal contractor: AMGEN INC.AI match · 99%
  6. BIOTECHNOLOGY INNOVATION ORGANIZATION6 reports
    $9.6M reported (all issues)
  7. HARMONY BIOSCIENCES, LLC5 reports
    $870K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  8. Ionis Pharmaceutical, Inc.5 reports
    $150K reported (all issues)
  9. Public Citizen5 reports
    $448.6K reported (all issues)
  10. Association of Black Cardiologists4 reports
    $120K reported (all issues)
  11. Personalized Medicine Coalition4 reports
    $170K reported (all issues)
  12. THE ALS ASSOCIATION4 reports
    $120K reported (all issues)
  13. The Mended Hearts, Inc.4 reports
    $240K reported (all issues)
  14. Genentech USA, Inc.3 reports
    $150K reported (all issues)Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  15. ALEXION PHARMACEUTICALS INC.2 reports
    $160K reported (all issues)Federal contractor: ALEXION PHARMACEUTICALS INC$733.6K in contracts, FY2026AI match · 99%
  16. AstraZeneca Pharmaceuticals LP2 reports
    Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  17. Healthcare Leadership Council2 reports
    $380K reported (all issues)
  18. VERTEX PHARMACEUTICALS INCORPORATED2 reports
  19. GENENTECH INC.1 report
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  20. MERCK & CO., INC.1 report
    Federal contractor: MERCK SHARP & DOHME LLC$445.3K in contracts, FY2026AI match · 100%

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.